Pharmacological Reports最新文献

{"title":"Adolescent fluoxetine exposure as a developmental cause of anxiety-like behavior in adult female mice.","authors":"Jessica A Garcia, Christopher A Frausto, Sergio D Iñiguez","doi":"10.1007/s43440-026-00922-x","DOIUrl":"https://doi.org/10.1007/s43440-026-00922-x","url":null,"abstract":"<p><strong>Background: </strong>The selective serotonin reuptake inhibitor (SSRI) fluoxetine (FLX) is a first-line pharmacological treatment for mood-related illnesses in the adolescent population - in which girls exhibit approximately twice the risk of being diagnosed with such disorders. Despite increasing FLX prescription rates in adolescents, the potential for unexpected long-term side effects remains poorly understood. To address this issue, we evaluated whether juvenile FLX exposure alters baseline responses to anxiety-inducing environments in adulthood.</p><p><strong>Methods: </strong>Adolescent female C57BL/6 mice received FLX (20 mg/kg) for 15 consecutive days (postnatal day [PD] 35-49). Three weeks later, once the mice reached adulthood (PD70), separate groups of mice were evaluated on the novelty suppressed feeding test or the elevated plus maze, two behavioral tasks validated for the assessment of anxiety-related responses.</p><p><strong>Results: </strong>We found that adult female mice with adolescent FLX pre-exposure displayed decreases in body weight and exploratory behavior in the elevated plus maze, along with a longer latency to initiate feeding behavior in the novelty suppressed feeding test, without changes in locomotor activity.</p><p><strong>Conclusion: </strong>Our data show that adolescent exposure to FLX results in anxiety-like phenotypes in adulthood, suggesting that early-life SSRI exposure may induce long-term changes in neural circuits regulating affective-related behavior.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149334876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of highly specific bacterial L-asparaginase through genome-wide computational screening and experimental validation.","authors":"Maciej Janicki, Andrzej Zielezinski, Izabela Pieróg, Joanna Śliwiak, Agnieszka Ludwików, Wojciech M Karlowski, Mariusz Jaskolski, Joanna I Loch","doi":"10.1007/s43440-026-00917-8","DOIUrl":"https://doi.org/10.1007/s43440-026-00917-8","url":null,"abstract":"<p><strong>Background: </strong>Bacterial L-asparaginases are key therapeutics for acute lymphoblastic leukemia (ALL), but their clinical efficacy is limited by off-target L-glutaminase co-activity, which contributes to severe side effects. This study aimed to identify highly specific bacterial L-asparaginases with minimal L-glutaminase co-activity.</p><p><strong>Methods: </strong>We screened ~ 85,000 prokaryotic genomes using a workflow integrating AlphaFold2 structure prediction, molecular docking, binding-energy estimation, and molecular dynamics simulations. Six top-ranked enzymes were selected for experimental validation.</p><p><strong>Results: </strong>RhAII protein from Acidobacteriota sp. showed high specificity toward L-asparagine (L-Asn), with a Michaelis constant (K_M) of 12 ± 2 µM and turnover number (k_cat) of 34 ± 2 s⁻¹, and negligible L-glutaminase activity. Molecular dynamics (MD) simulations revealed a relationship between enzyme activity and the conformational dynamics of the flexible gating element (FGE), characterized by residue-level root mean square fluctuation (RMSF), and L-Asn positional fluctuations, evaluated by ligand root mean square deviation (RMSD) relative to the protein. High L-asparaginase activity was associated with optimal FGE dynamics and low L-Asn RMSD, consistent with stable substrate positioning within the active site. In contrast, enzymes with altered FGE dynamics relative to the reference EcAII enzyme from Escherichia coli, such as PoAII from Planctomycetota sp., showed poor L-asparaginase performance (K_M 5797 ± 1143 µM; k_cat 1.2 ± 0.1 s⁻¹).</p><p><strong>Conclusions: </strong>Genome- and structure-guided screening identified RhAII as a promising antileukemic candidate for further validation in biological models. A key limitation of the computational workflow was the lack of correlation between predicted substrate binding energies and catalytic efficiency, highlighting the importance of active-site dynamics in enzyme kinetics.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149334878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety profile of advanced therapies in Crohn's disease: a systematic review and network meta-analysis.","authors":"Kinga Kasprowicz, Paweł Moćko, Katarzyna Śladowska, Przemysław Holko, Paweł Kawalec","doi":"10.1007/s43440-026-00918-7","DOIUrl":"https://doi.org/10.1007/s43440-026-00918-7","url":null,"abstract":"<p><strong>Background: </strong>Crohn's disease (CD) is a chronic inflammatory bowel disorder characterized by a relapsing-remitting course and substantial heterogeneity in clinical presentation. This study aimed to assess the comparative efficacy and safety of approved biologic and small-molecule therapies for CD, with particular emphasis on guselkumab and mirikizumab.</p><p><strong>Methods: </strong>A systematic review and frequentist network meta-analysis (NMA) was conducted in accordance with PRISMA-NMA, the Cochrane Handbook, and ISPOR guidelines. MEDLINE, EMBASE, and the Cochrane Library were searched from inception to June 2026. Phase 3 randomized controlled trials (RCTs) evaluating adalimumab, guselkumab, infliximab, mirikizumab, risankizumab, vedolizumab, upadacitinib, or ustekinumab in adults with CD were included.</p><p><strong>Results: </strong>A total of 27 RCTs were included. During induction therapy, guselkumab 400 mg achieved the highest P-scores for both clinical response and remission and was associated with higher odds of these outcomes compared with placebo and several active comparators. Mirikizumab was also more effective than placebo but ranked in the middle of the treatment hierarchy. During maintenance therapy, guselkumab 200 mg and 100 mg achieved the highest rankings for clinical response and remission; however, differences between guselkumab and several active comparators were not statistically significant. These comparisons were predominantly informed by indirect evidence and should not be interpreted as establishing definitive clinical superiority. No consistent evidence of major safety differences was observed across interventions; however, heterogeneity and inconsistency in several safety networks limited the certainty of the comparisons. Although guselkumab achieved favourable rankings for serious adverse events and serious infections, few statistically significant differences were observed between active treatments. The results should be interpreted in the context of indirect comparisons and methodological heterogeneity among included studies.</p><p><strong>Conclusions: </strong>Within the limitations of an NMA based predominantly on indirect evidence, guselkumab achieved the highest rankings for several efficacy outcomes during both induction and maintenance therapy. Mirikizumab showed higher odds of response and remission than placebo, although its node was informed by a single eligible phase 3 study. Given differences in study populations and trial designs, particularly in maintenance studies, these findings should be interpreted cautiously and not as evidence of definitive clinical superiority.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149334877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic impact of cardioselectivity of beta-blockers prescribed during hospitalization for decompensated heart failure.","authors":"Otto Mayer, Josef Jirák, Jan Filipovský","doi":"10.1007/s43440-026-00927-6","DOIUrl":"https://doi.org/10.1007/s43440-026-00927-6","url":null,"abstract":"<p><strong>Background: </strong>Beta-blockers (BBs) show considerable variation in cardioselectivity (i.e., the relative affinity to the β₁ receptor), even among those with evidence of benefit in the treatment of chronic heart failure (HF). We aimed to evaluate whether the cardioselectivity of BBs prescribed during hospitalization for decompensated HF will affect the long-term prognosis of patients.</p><p><strong>Methods: </strong>In the prospective study, we followed 4053 patients hospitalized for decompensated HF. The entire cohort was divided into subgroups based on the cardioselectivity of recommended BBs (as stated in discharge summary).</p><p><strong>Results: </strong>After complex adjustment, patients treated with a highly selective BB (bisoprolol) showed significantly lower five-year cardiovascular mortality than those with a lesser degree of cardioselectivity (mainly metoprolol) [hazard ratio (HR) 0.69 (95% confidence interval (CI): 0.52-0.92), p = 0.011]. This difference remained in patients with HF with reduced ejection fraction (HFrEF) [HR 0.58 (95% CI: 0.37-0.89), p = 0.013], but was not yet significant in HF with preserved ejection fraction (HFpEF) [HR 0.66 (95% CI: 0.43-1.02), p = 0.063]. In HFrEF patients only, highly cardioselective BBs also showed a lower risk of cardiovascular mortality than nonselective BBs with vasodilatory properties (mainly carvedilol) [HR 0.55 (95% CI: 0.33-0.93), p = 0.025].</p><p><strong>Conclusion: </strong>The choice of a BB regarding the degree of its cardioselectivity may have a prognostic impact in chronic HF patients.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149334879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interaction of the serotonergic system and GPR39 zinc receptor in antidepressant-like response in mice.","authors":"Dominika Siodłak, Urszula Doboszewska, Katarzyna Mlyniec","doi":"10.1007/s43440-026-00896-w","DOIUrl":"https://doi.org/10.1007/s43440-026-00896-w","url":null,"abstract":"<p><strong>Background: </strong>Zinc and 5-HT1A receptors have both been implicated in modulating CREB/BDNF/TrkB pathway when exerting their antidepressant-like effects. That pathway is an important regulator of neuroplasticity, shown to be sensitive to serotonergic and zinc-dependent signalling. This study aimed to determine whether co-administration of GPR39 and 5-HT1A receptor agonists produces antidepressant-like responses in mice and whether these effects are associated with changes in proteins of the CREB/BDNF/TrkB pathway and selected serotonergic markers.</p><p><strong>Methods: </strong>Male CD1 mice received inactive doses of TC-G 1008 (GPR39 agonist, 5 mg/kg) and 8-OH-DPAT (5-HT1A agonist, 1 mg/kg). Antidepressant-like effects following acute, subacute and chronic treatment were assessed using the forced swim test (FST). Western blot analysis examined the levels of CREB-BDNF-TrkB pathway proteins in the prefrontal cortex and hippocampus. In GPR39 knock-out (KO) mice, chronic 8-OH-DPAT treatment was further evaluated in FST alongside measurements of CREB-BDNF-TrkB, 5-HT1A, 5-HT7 and SERT protein levels in aforementioned structures.</p><p><strong>Results: </strong>Combined treatment with TC-G 1008 and 8-OH-DPAT reduced immobility in the FST across all treatments durations. Neither treatment nor GPR39 expression affected CREB-BDNF-TrkB protein levels. However, chronic co-treatment increased hippocampal SERT levels in wild-type mice, while producing opposite effects on 5-HT7 protein levels in the prefrontal cortex of GPR39 KO mice.</p><p><strong>Conclusions: </strong>The rapid antidepressant-like effects of combined TC-G 1008 and 8-OH-DPAT treatment appear independent of the CREB-BDNF-TrkB pathway. Differences in SERT and 5-HT7 protein levels between wild-type and GPR39 KO mice suggest that GPR39 modulates serotonergic system responsiveness to antidepressant treatment.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149323919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic opportunities of marine-derived bioactive compounds against SARS-CoV-2 and other enveloped viruses.","authors":"Thananjeyan Balasubramaniyam, Shailima Rampogu, Youyeon Go, Vinod Kumar Nathan, Robert Zdanowski, Jacek Z Kubiak","doi":"10.1007/s43440-026-00920-z","DOIUrl":"https://doi.org/10.1007/s43440-026-00920-z","url":null,"abstract":"<p><p>Marine ecosystems are a vast, underexplored reservoir of bioactive compounds with unique structural diversity and potent biological activities. Enveloped viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, continue to pose significant global health threats, exacerbated by emerging variants, limited therapeutic options beyond vaccines, and challenges such as drug resistance and immune dysregulation. Compounds derived from marine organisms, including lectins (e.g., griffithsin from red algae Griffithsia sp.), sulfated polysaccharides (e.g., iota-carrageenan from red algae Chondrus crispus), polyphenols (e.g., dieckol from brown algae Ecklonia cava), and depsipeptides (e.g., plitidepsin from tunicates), have shown promising antiviral effects in preclinical studies. These molecules primarily act by inhibiting viral entry (via the spike glycoprotein or glycan binding), replication (targeting proteases such as the main protease [Mpro] and the RNA-dependent RNA polymerase [RdRp]), or by modulating host immune responses (e.g., reducing cytokine storms or oxidative stress). In vitro, in vivo, and in silico evidence highlights their potential against SARS-CoV-2 and related enveloped viruses (e.g., HIV, HSV, influenza, HCMV), which share mechanistic similarities, including envelope-mediated fusion and RNA-based replication. This narrative review provides a cohesive overview of selected marine-derived bioactive compounds with reported activity against SARS-CoV-2 and other enveloped viruses. It examines their sources, structural features, mechanisms of action, key activity metrics (e.g., IC₅₀/EC₅₀ values), and translational prospects, and addresses challenges such as scalability, preclinical-to-clinical gaps, and sustainability aligned with the European Blue Economy. By integrating recent findings, this review aims to highlight promising leads and guide future research toward innovative, broad-spectrum antiviral therapies.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149323920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Introduction to the special issue: novel drug targets and therapeutic approaches in gliomas.","authors":"Monika Szeliga","doi":"10.1007/s43440-026-00916-9","DOIUrl":"https://doi.org/10.1007/s43440-026-00916-9","url":null,"abstract":"","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149299777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of repeated administration of lumateperone on cytochrome P450 expression and activity in rat liver.","authors":"Przemysław J Danek, Renata Pukło, Władysława A Daniel","doi":"10.1007/s43440-026-00921-y","DOIUrl":"https://doi.org/10.1007/s43440-026-00921-y","url":null,"abstract":"<p><strong>Background: </strong>Antipsychotic drugs are used for long-term treatment of schizophrenia and other psychotic-related symptoms. Our present work aimed at investigating the effects of chronic administration of the third-generation antipsychotic drug lumateperone on the expression of cytochrome P450 (CYP) enzymes involved in drug metabolism and transcription factors in rat liver.</p><p><strong>Methods: </strong>Male Wistar rats received lumateperone (1 mg/kg) once daily for 14 days. 24 h after the last dose, their livers were excised, and CYP enzyme expression and activity were measured. In addition, the expression of transcription factors and serum hormone concentrations were evaluated.</p><p><strong>Results: </strong>Lumateperone significantly increased the CYP expression and/or activity of CYP2A, CYP2B, and CYP3A enzymes, but decreased that of CYP2D enzymes. The observed changes in CYP enzymes were in line with alterations in transcription factors: lumateperone elevated the mRNA level of PXR and reduced that of FXR in the liver. Simultaneously, increased corticosterone levels and decreased T₄ levels in serum were observed.</p><p><strong>Conclusion: </strong>Repeated lumateperone administration modulated the expression and activity of selected hepatic CYP enzymes in rats. These findings indicate biological effects on hepatic drug-metabolizing pathways in a rat model. Relevance to human drug-drug interactions remains to be established in in vitro pharmacokinetic studies.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149272127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycation stress in glioma: a metabolic vulnerability and therapeutic target.","authors":"Sonia B Umdor, Ellora Sen","doi":"10.1007/s43440-026-00904-z","DOIUrl":"https://doi.org/10.1007/s43440-026-00904-z","url":null,"abstract":"<p><p>Gliomas are primary brain tumors characterized by genetic heterogeneity, metabolic reprogramming, and resistance to therapy, which collectively contribute to tumor progression and aggressive clinical behavior. Heightened aerobic glycolysis in these tumors is associated with altered glycolytic flux and dysregulated metabolic landscape. The ubiquitous dicarbonyl metabolite methylglyoxal (MGO) is a highly reactive glycating agent produced from glycolytic intermediates. MGO is a major precursor of advanced glycation end products (AGEs), and excessive AGE accumulation is associated with disruption of cellular homeostasis. Inhibitors of key bioenergetic pathways have shown potential in glioma, indicating that altered glycolysis may create metabolic vulnerabilities that influence tumor cell survival. In this context, increased glycolytic flux in glioma may provide a mechanistic link between glycation stress and tumor progression. This review discusses the influence of glycation stress in glioma biology and emphasize the importance of considering genetic heterogeneity, redox landscape, and metabolic comorbidities to better understand glycation burden and inform therapeutic strategies.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149245822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse events during cystic fibrosis transmembrane conductance regulator modulator therapy in children with cystic fibrosis: an observational study.","authors":"Marta Osińska, Beata Narożna, Ewa Sapiejka, Paulina Famulska, Katarzyna Tąpolska-Jóźwiak, Anna Steinert-Dymecki, Aleksandra Kozłowska, Maria Jóźwiak, Joanna Nowakowska-Lewicka, Agnieszka Bienert, Irena Wojsyk-Banaszak","doi":"10.1007/s43440-026-00919-6","DOIUrl":"https://doi.org/10.1007/s43440-026-00919-6","url":null,"abstract":"<p><strong>Background: </strong>Cystic fibrosis (CF) is a life-limiting genetic disease caused by pathogenic variants in the CFTR gene. CFTR modulators (CFTRms) have substantially improved clinical outcomes, but real-world data on symptoms reported during therapy in pediatric populations remain limited. This study evaluated the frequency and distribution of adverse events (AEs) reported during 12 months of CFTR modulator (CFTRm) therapy in pediatric and adolescent patients with CF.</p><p><strong>Methods: </strong>This prospective, dual-center observational study conducted in Poland included 74 patients aged 2-18 years receiving lumacaftor/ivacaftor (LI), tezacaftor/ivacaftor (TI), or elexacaftor/tezacaftor/ivacaftor (ETI). Reported symptoms were monitored prospectively and categorized as respiratory, nervous system, gastrointestinal, or other AEs. AE profiles according to patient characteristics and CFTRm regimen were explored.</p><p><strong>Results: </strong>At least one adverse event (AE) was reported by 90.5% of patients during follow-up. AE involving the respiratory and nervous systems were the most frequently reported, occurring in 79.7% and 75.7% of patients, respectively. Most AEs were intermittent and rarely required treatment interruption (n = 3). Lung function and nutritional status improved significantly during therapy. The overall frequency of reported AEs did not differ depending on the FEV₁ or BMI outcomes. Nervous system AEs were more frequently reported among patients aged > 10 years and among patients receiving ETI compared with LI.</p><p><strong>Conclusions: </strong>CFTRm therapy was generally well tolerated in this pediatric CF cohort. Reported AEs were common but predominantly intermittent and rarely led to treatment interruption. Systematic monitoring remains important, particularly for neurological symptoms, to better characterize tolerability of CFTRm therapy.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149245783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}